The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

PROVEN EFFICACY IN SCALP PSORIASIS1*

Sustained improvement in scalp psoriasis up to 1 year1,a,b

Created with Highcharts 8.0.4OTEZLA 30 mg BIDCrossover to OTEZLA 30 mg BIDPlacebo020406080100Highcharts.com
Week 16
(n = 37)
(n = 44)
Week 32
(n = 37)
(n = 44)
Week 52
(n = 32)
(n = 43)
Patients Achieving ScPGA Score
of 0 or 1 (%)
63%
54%
Sustained_improvement_in_scalp_psoriasis
Woman holding a pot of flowers

aESTEEM 2 study. Data as observed; includes patients who were randomized to OTEZLA 30 mg BID or placebo at baseline, were PASI-50 responders at week 32, and who continued to receive OTEZLA 30 mg BID up to week 52.

bAt week 16, ScPGA score of 0 (clear) or 1 (minimal) achievement was significantly greater with OTEZLA 30 mg BID (40.9%, 72/176) vs placebo (17.2%, 16/93); P < 0.0001; FAS, LOCF.

OTEZLA clears or minimizes scalp psoriasis1

See the OTEZLA difference

Real patients, real pictures.

Actual patient with scalp psoriasis before treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Baseline

Actual patient with scalp psoriasis after 16 weeks of treatment with OTEZLA® (apremilast). Please see full Important Safety Information.

Week 16

Individual results may vary.

*Among patients with moderate to very severe scalp psoriasis at baseline (ScPGA score ≥3; n = 269/411, 65.5%).

Photos taken from the ESTEEM clinical trial program, which evaluated OTEZLA 30 mg BID in patients with active plaque psoriasis.

BID, twice daily; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; FAS, full analysis set; LOCF, last observation carried forward; PASI, Psoriasis Area and Severity Index; ScPGA, Scalp Physician Global Assessment.

OTEZLA SUSTAINS IMPROVEMENT IN SCALP PSORIASIS2,3

Significant and sustained improvement in scalp psoriasis2,3,a

Scalp-Data
Learn about treating moderate to severe plaque psoriasis with OTEZLA® (apremilast)

aLIBERATE study. mITT, LOCF. Includes patients with ScPGA ≥3 (moderate or greater) at baseline. Response at week 16 and week 104 was determined using the LOCF methodology. Week 104 analysis includes patients who entered the apremilast extension phase and were treated in the phase.

bP = 0.0458, OTEZLA vs placebo.

Scalp response was sustained for up to 2 years with OTEZLA3

BID, twice daily; BL, baseline; DLQI, Dermatology Life Quality Index; ESTEEM, Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis; VAS, visual analogue scale.

References:

  1. Crowley J, Gooderham M, Wasel N, et al. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients With Nail, Scalp, and Palmoplantar Psoriasis: 52-Week Results From the ESTEEM 2 Trial. Presented at: the 73rd Annual Meeting of the American Academy of Dermatology; March 20-24, 2015; San Francisco, CA.
  2. Reich K, Gooderham M, Green L, et al. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE). J Eur Acad Dermatol Venerol. 2017;31(3):507-517.
  3. Reich K, Gooderham M, Bewley A, et al. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study. J Eur Acad Dermatol Venereol. 2018;32(3):397-402.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.